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Background: Trials of complex interventions are criticized for being ‘black box’, so the UK Medical Research Council
recommends carrying out a process evaluation to explain the trial findings. We believe it is good practice to pre-specify
and publish process evaluation protocols to set standards and minimize bias. Unlike protocols for trials, little guidance
or standards exist for the reporting of process evaluations. This paper presents the mixed-method process evaluation
protocol of a cluster randomized trial, drawing on a framework designed by the authors.
Methods/design: This mixed-method evaluation is based on four research questions and maps data collection to a
logic model of how the data-driven quality improvement in primary care (DQIP) intervention is expected to work. Data
collection will be predominately by qualitative case studies in eight to ten of the trial practices, focus groups with
patients affected by the intervention and quantitative analysis of routine practice data, trial outcome and questionnaire
data and data from the DQIP intervention.
Discussion: We believe that pre-specifying the intentions of a process evaluation can help to minimize bias arising
from potentially misleading post-hoc analysis. We recognize it is also important to retain flexibility to examine the
unexpected and the unintended. From that perspective, a mixed-methods evaluation allows the combination of
exploratory and flexible qualitative work, and more pre-specified quantitative analysis, with each method contributing
to the design, implementation and interpretation of the other.
As well as strengthening the study the authors hope to stimulate discussion among their academic colleagues about
publishing protocols for evaluations of randomized trials of complex interventions.
Data-driven quality improvement in primary care trial registration: ClinicalTrials.gov: NCT01425502
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Trials of complex interventions are often criticized as
being a black box because it is difficult to know exactly
why an intervention did (or did not) work. The UK
Medical Research Council’s framework for designing and
evaluating complex interventions recommends conduct-
ing a process evaluation in order to ‘explain discrepancies
between expected and observed outcomes, to understand* Correspondence: a.m.grant@dundee.ac.uk
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reproduction in any medium, provided the orhow context influences outcomes, and to provide insights
to aid implementation [1].’ However, when designing our
own process evaluation of a cluster randomized trial of a
complex intervention, [2] we found little specific guidance.
In response, we have proposed a framework to guide
process evaluation design [3].
Pre-specifying and publishing protocols are recognized
as improving the standards of clinical trials, by allowing
comparison of what was intended with what was actually
done. Although process evaluations are somewhat differ-
ent (since flexibility to evaluate unexpected findings quali-
tatively will often be useful), we believe that publication oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pre-specifying the intentions of process evaluations can
help to minimize bias arising from potentially misleading
post-hoc analysis. Unlike trial protocols, there is little
explicit guidance or standards for the reporting of
process evaluation protocols. We hope publishing this
protocol will help stimulate discussion among the aca-
demic community.
This paper briefly describes the trial being evaluated,
presents a logic model detailing the trial hypothesized
pathway of change, and states the research questions
that arise from our assumed model of trial processes,
overall study design, and detailed methods for answering
each question.
Data-driven quality improvement in primary care trial
High-risk prescribing of non-steroidal anti-inflammatory
drugs (NSAIDs) and antiplatelet agents account for a
significant proportion of hospital admissions, due to pre-
ventable adverse drug events [4,5]. We are conducting a
randomized controlled trial of a complex intervention to
improve prescribing safety of these drugs in 40 general
practices in two Scottish Health Boards (the DQIP trial).
The trial is fully described in the published protocol [2].
In brief, the DQIP intervention comprises three compo-
nents. The first component is a web-based informatics
tool that provides weekly updated feedback of targeted
prescribing at practice level. This prompts the review of
individual patients affected and summarizes each patient’s
relevant risk factors and prescribing. The second compo-
nent is an educational outreach visit that highlights the
risks of the targeted prescribing and provides training in
the use of the tool. The final component is a fixed pay-
ment of 350 GBP (560 USD; 403 EUR) to each practice up
front and a fee-for-service payment of 15 GBP (24 USD;
17 EUR) for each patient reviewed.
The trial has a stepped wedge design, [6,7] where all
participating practices receive the DQIP intervention.
These practices are randomized to one of ten different
start dates, with each practice functioning as its own
control in a time series analysis. The primary outcome
measure is a composite of nine measures of high-risk
NSAID and antiplatelet prescribing. A separate eco-
nomic evaluation is planned.
Structure/framework of DQIP parallel process evaluation
protocol
Drawing on our proposed framework for designing process
evaluations of cluster randomized trials, [3] Figure 1 shows
the processes we assume have to occur for the intervention
to be effective, and therefore explicitly identifies targets for
evaluation. This logic model underlies the process evalu-
ation design and data collection, although resource con-
straints inevitably require prioritization.DQIP process evaluation aim and research questions
Aim
The aim of this study is to understand DQIP delivery,
implementation and translation into reducing high risk
prescribing.
Research questions:
1. How do different practices adopt the intervention and
how does this influence their delivery to targeted
patients and whether they continue to use the
intervention? Are there any positive or negative
unintended consequences from a practice perspective?
2. How do patients respond to the intervention? Are
there any positive or negative unintended
consequences from a patient perspective?
3. How are practice organizational characteristics
associated with variation in recruitment, adoption,
reach, delivery to the patient, and maintenance?
4. Does effectiveness vary between practices, and if so,
how are practice characteristics and processes
including structure, adoption, reach, delivery to the
patient, and maintenance associated with effectiveness?
Management and governance
Research ethical approval for this study was granted
by Fife and Forth Valley Research Ethics Committee
(11/AL/0251). An external Trial Steering Committee and
an overall Program Advisory Group, consisting of inde-
pendent professional and lay people, have been established
and both meet bi-annually.
Methods/design
Overall study design
The study is a mixed-methods parallel process evalu-
ation. It will include a qualitative dominant case-study
approach in a purposeful sample of practices and a
hypothesis-testing quantitative analysis of data from all
practices. Data collection and analysis will be conducted
in parallel to the DQIP trial itself.
Methods for research question 1
Study design
Study will be a primarily qualitative, mixed-methods in-
depth case-study in a sample of eight to ten practices.
Sampling
Sampling for this study will be purposive and ensure
heterogeneity in list size, reflecting our prior expectation
that effectiveness will be greater in small practices; [8]
and initial use of the tool (since this is how patients for
review are identified and so a key process if our logic
model is true); and the date the practice started the trial
(which is randomized, but workload in general practice is
strongly seasonal, so resource to deliver the intervention
Figure 1 Data-driven quality improvement in primary care (DQIP) trial hypothesized pathway of change and process evaluation model.
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from the first two cohorts of starting date and develop
theories that can then be tested in the subsequent case
studies [9].
Qualitative data collection
Data collection will use a variety of methods, in order to
understand how intervention processes were perceived
and implemented in each practice, and how these pro-
cesses influence observed trial outcomes [10]. As part of
the intervention in all practices, the qualitative re-
searcher will assist the research pharmacist in delivering
the education and training to the trial practices, and
make field notes detailing attendance and the practice’s
response. Any additional communication or practice vis-
its will be recorded in the same way. These data will in-
form the focus of the interviews in each practice, and
additionally be used to help construct a detailed, ‘rich’
description of each practice for cross-case analysis [11].
General practitioners (GPs), practice pharmacists and
practice managers, from the case-study practices, involved
in delivering the DQIP intervention to patients will be
invited to interview approximately six months after the
practice starts the trial. Depending on practice size and
how each practice has organized DQIP work, we will
interview one to three professionals per practice. At a
minimum, the GP most involved in DQIP will be inter-
viewed, but other GPs involved, the practice manager andthe practice pharmacist will also be interviewed. Partici-
pants will be asked about their experience of the interven-
tion, the practice process for review, how the intervention
fitted with their existing work, barriers and facilitators,
maintenance over time, and any perceived unintended
consequences. Where possible, the GP most involved in
DQIP will be re-interviewed three to six months later, to
explore changes over time and the factors involved in
maintaining and sustaining use of the tool. Interviews will
be conducted at a time and place of the participant’s
choosing, facilitated by a topic guide drawing on the logic
model and Normalization Process Theory (NPT), [12] and
with the participant’s permission, audio-recorded for tran-
scribing. Normalization Process Theory is a sociological
theory designed to understand how practices or interven-
tions are implemented and become embedded into every-
day work (normalized and routinized). NPT is made up of
four domains, coherence, cognitive participation, collect-
ive action, reflective monitoring, with each of these
domains divided into four categories [12].
Qualitative data analysis
The professional qualitative data will be inductively and
deductively analyzed in separate NVivo 8 (QSR Inter-
national, Southport, UK) databases. Deductive analysis
will be by examining the data through the lens of NPT
[12]. Our pilot work has illustrated that this means of
analysis sometimes ‘divides’ emergent codes in the data.
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to allow themes to emerge from the data and to explore
issues that the NPT deductive analysis may be less suited
to identify and examine.
Case-study analysis
For each practice (case), we will have a set of quantitative
and qualitative data which can be synthesized. Quantita-
tive data, as described in detail below, will be used to de-
scriptively characterize each practice in terms of practice
structural characteristics, and measures of adoption, deliv-
ery to patient, reach, and maintenance. Qualitative data
includes field notes relating to research team contacts
with each practice and interview data. Synthesis of the
qualitative and quantitative data for the case studies will
take two forms; first a comprehensive, ‘rich’ description of
each case-study practice will be created based on all data,
then this description will be used to conduct a cross-case
comparison based on the logic model [13]. The aim of this
analysis is to examine in detail how practices implement
(or not) the processes that our logic model assumes are
required to deliver change in high-risk prescribing, and
how these processes appear to influence effectiveness in
each practice. The aim of this sequential merging of quali-
tative and quantitative data is not triangulation but
crystallization where we are using the qualitative data to
explain the quantitative [14,15]. This offers the advantage
of allowing the qualitative data to explore complex, unex-
pected or contradictory quantitative data collected from
the tool and adoption questionnaires. A constant compari-
son and deviant case approach will be adopted [16]. Con-
stant comparison will allow the researcher to test the
emerging hypothesis by comparing different case-study
practices. Any deviant examples from the emergent hy-
pothesis will be examined. Analysis will initially be simul-
taneous with data collection to allow the emerging
analysis to be tested and revised in subsequent data sam-
pling, collection and analysis. The framework [17] analysis
technique will be used to support within-case and cross-
case analysis.
Methods for research question 2
Study design
The design is that of a focus group study involving a
sample of patients targeted by the intervention.
Sampling
Four to six of the case-study practices will invite patients
who have been targeted by the intervention to attend a
focus group.
Data collection
One focus group per practice will be held. The focus
group will have two stages. First, the patients will beasked about their experience of medication reviews and
the extent to which they were aware of the intervention
(response). Then after watching a short presentation
about the way clinical data is being used in this study,
patients will be asked about their experience, percep-
tions and any consequences of the intervention triggered
by review or medication change and their attitudes and
beliefs about the way in which clinical data is being
used.
Data analysis
Patient focus group data will be analyzed inductively to
allow themes to emerge from the data. The framework
technique [17] will be used to facilitate analysis.
Methods for research questions 3 and 4
Study design
The study requires quantitative analysis of routinely
available data about practices, trial process data gener-
ated by DQIP informatics tool, practice questionnaire
data, and trial outcome data. We hypothesize that practice
organizational characteristics and adoption will be asso-
ciated with the level of reach, delivery to the patient and
maintenance achieved, and that lower levels of reach,
delivery to the patient and maintenance will be associated
with lower effectiveness. The specific hypotheses to be
tested will be based on findings from the case studies.
Sampling
Data will be collected for all practices.
Data collection
Multiple datasets will be collected and linked. Practice
characteristics will be measured using routinely available
data including list size, rurality , deprivation, proportion
of older patients, postgraduate training status, dispens-
ing status, contract type (nGMS, section 17c/2c), Health
Board, Community Health Partnership, overall QOF
clinical performance, and QOF performance on relevant
medicines management indicators (Medicines 6, 10, 11,
12){National Institute of Clinical Excellence, 2012}. Base-
line levels of the high risk NSAID and antiplatelet
prescribing being targeted will also be available for par-
ticipating practices. During the recruitment of clusters
we will document the trial recruitment process and care-
fully record those practices that are approached, those
that respond and those that are recruited. Participating
and non-participating practices will be compared using
available practice characteristic data. Adoption will be
measured using a quantified assessment of engagement
with the education outreach based on which practice
members attended and field notes of the interaction, and
by a survey instrument developed for the trial and com-
pleted at trial start and after six to nine months based
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the four domains of NPT, with the baseline survey fo-
cusing on coherence and cognitive participation, and the
follow-up survey collecting additional data on collective
action and reflective monitoring. Reach will be measured
as the proportion of patients identified by the informat-
ics tool who are actually reviewed. Delivery to the pa-
tient will be measured in terms of patterns of review
recorded in the tool (which measures were focused on,
how they were carried out [records review, face-to-face
consultation, telephone consultation]), the decisions
made (the proportion of patients who decide to con-
tinue, the proportion who decide to continue with gas-
tric protection and the proportion who decide to stop
the drug). Maintenance will be measured in terms of
how reach changes over time. Effectiveness will be mea-
sured in terms of the trial primary outcome (the high
risk NSAID/antiplatelet composite) and the two second-
ary outcomes of ‘repeated’ and ‘new’ prescribing (since
the intervention targets the review of repeated prescrib-
ing, with an expectation that the experience of reviewing
will reduce new prescribing as well, but that this may
vary by practice and particularly by practice size).
Data analysis
Initial descriptive analysis will use practice characteristics
data to compare participating practices with the wider
population of practices in the two Boards and nationally
(to assess the representativeness of recruited practices and
the implications for generalizability). The overall extent of
reach, delivery to the patient and maintenance will then
be examined, and univariate and multivariate associations
with practice characteristics and adoption will be exam-
ined using cross-tabulations, comparison of means, and
logistic/linear regression as appropriate to the data. The
extent of variation between practices in the three specified
measures of effectiveness will be examined using multilevel
logistic regression, and associations between effectiveness
and practice characteristics, adoption, reach, delivery to
the patient, and maintenance will be examined.
Synthesizing results from all three studies
Synthesis across the three studies will have several
elements:
1. The quantitative study will inform case-study
sampling and will help contextualize sampled
settings.
2. The case and patient focus group studies will provide
a rich understanding of how the intervention was
perceived and implemented, and how actual
implementation related to our model of how the
intervention was intended to work. These data will
generate hypotheses for testing in the quantitativestudy, and will provide the flexibility either to
identify key processes on the assumed pathway
quantitatively or to identify unexpected processes
that are not in the logic model, or both.
3. The quantitative study will test hypotheses generated
from the qualitative analysis, and help inform
judgments about generalization of the case and
focus group studies.
4. Overall synthesis will draw on findings from all three
studies, which will be used to construct a narrative
synthesis of the process of implementation of the
intervention, to contextualize the main trial findings
(whether positive or negative) and to inform
judgments about external validity and generalizability
, real-world implementation if appropriate, and
further intervention development [18].
Discussion
We have piloted these data collection methods in four
general practices and in six focus groups with patients
from these practices and with members of the public.
These methods have been acceptable to practitioners
and patients and have generated sufficient data to feas-
ibly evaluate this complex intervention trial. The pilot
has influenced the focus and design of this evaluation
and the associated topic guides and questionnaires.
As in any study, choices have been made in the design
of this process evaluation protocol that balance ideal re-
search questions with feasibility and resource constraints.
[19] We believe that a prior design of the process evalu-
ation that maps to expectations about how the interven-
tion will work strengthens the study. It is also important,
however, to retain the flexibility needed for examining the
unexpected and the unintended. From that perspective, a
mixed-methods evaluation allows the combination of
exploratory and flexible qualitative work, and more pre-
specified quantitative analysis, with each method contrib-
uting to the design, implementation and interpretation of
the other [20]. Design is always constrained by the
resources available though, and although we have been
fortunate in being relatively well-resourced for this elem-
ent of the project, our chosen case-study method does
mean having to sample a relatively small number of prac-
tices to carry out the qualitative work. Inevitably though,
extending the interviewing to a larger number of practices
would involve less depth in each practice, and we chose to
prioritize more depth in a case-study approach using mul-
tiple interviews in selected practices.
We have also chosen to conduct a parallel process
evaluation, where data collection is simultaneous with trial
implementation [21]. A key advantage is that data collec-
tion is contemporaneous with the practices actually doing
the work of implementation, but a potential disadvantage
is the risk that the case-study practices vary little in their
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post-hoc design that samples based on main trial out-
comes would avoid this risk, but at the cost of being
designed after trial effectiveness is known, and conducted
long after the trial completes. Overall, we judged a parallel
process evaluation to be more likely to produce robust
findings, and although the protocol is pre-specified, the
methods proposed are flexible to unexpected findings in
that qualitative data collection and analysis is iterative in
nature, and will inform the choice of the actual hypotheses
to be tested quantitatively. A final potential weakness is
that some of the quantitative data is relatively thin. For ex-
ample, the data on the nature of review carried out is col-
lected routinely in the DQIP informatics tool but lacks
contextual information or much detail. This reflects a
trade-off between being able to collect data in all practices
and avoiding burdening practices with data collection that
has no clinical purpose.
Our study offers the opportunity to explain why or
why not the DQIP intervention reduced high risk pre-
scribing. If the intervention does not reduce high-risk
prescribing as intended, then the analysis will help iden-
tify why this happened in terms of where the assump-
tions of the logic model broke down, or call into
question the underlying model. If the intervention does
reduce high-risk prescribing, then the process evaluation
will provide information to inform judgments about
likely generalizability, and identify if improvement was
general or restricted to some practices which may influ-
ence real-world implementation or identify targets for a
modified intervention.
Trial Status
Active. Trial started 31st October 2011.
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